Related Experiment Videos
Phytoestrogens: endocrine disrupters or replacement for hormone replacement therapy?
Wolfgang Wuttke1, Hubertus Jarry, Tamara Becker
1Department of Clinical and Experimental Endocrinology, University of Göttingen, Robert-Koch-Strasse 40, 37075 Göttingen, Germany. ufkendo@med.unigoettingen.de
Maturitas
|March 1, 2003
Summary
Soy and red clover isoflavones show mild osteoprotective effects but do not improve menopausal symptoms. Cimicifuga racemosa extract BNO 1055, however, demonstrates beneficial effects without stimulating uterine growth, suggesting it as a potential alternative to hormone replacement therapy.
Area of Science:
- Phytoestrogens and Reproductive Health
- Pharmacology of Herbal Extracts
- Menopause Management
Background:
- Soy, red clover, and Cimicifuga racemosa are commonly used to manage menopausal symptoms.
- Their mechanisms of action, particularly as selective estrogen receptor modulators (SERMs), are not fully understood.
- Concerns exist regarding potential endocrine disruption and risks to reproductive tissues.
Purpose of the Study:
- To compare the effects of soy, red clover isoflavones, and Cimicifuga racemosa extract BNO 1055 on climacteric complaints and bone health.
- To evaluate their impact on the urogenital tract and risks to cardiovascular health, mammary, and endometrial tissues.
- To determine if these phytoestrogens meet the criteria for phyto-SERMs or act as endocrine disruptors.
Main Methods:
- Review of selected literature published since 1980.
- Inclusion of unpublished experimental and clinical results from the authors.
- Comparative analysis against classical hormone preparations.
Main Results:
- Soy/red clover isoflavones exhibit mild osteoprotective effects but do not alleviate climacteric complaints.
- These phytoestrogens may stimulate uterine and mammary tissue proliferation.
- Cimicifuga racemosa extract BNO 1055 demonstrated estrogenic effects in ovariectomized rats, including bone protection and reduced LH levels, without uterotrophic effects.
Conclusions:
- Soy and red clover isoflavones do not appear to be ideal SERMs.
- Cimicifuga racemosa extract BNO 1055 shows promise as an ideal SERM.
- BNO 1055 may offer a viable alternative to hormone replacement therapy if clinical studies confirm these findings.